An analysis of the planned data center buildout finds that AI needs around USD 3 trillion in annual revenue by 2030 to offer a conventional rate of return. Estimates of the required revenue vary among analysts, because they rest on assumptions about returns and …
Swiss drugmaker Roche has now joined companies including Eli Lilly in pushing toward a new frontier, testing whether treatment can do more than slow cognitive decline and prevent symptoms from emerging in the first place.
Central banks run on credibility as much as on capital. A governor who promises to do whatever it takes seldom has to prove it, because markets take him at his word. Nvidia, which investors have taken to calling "theCentral Bankof AI", has worked in …
Eli Lilly and Company filed an 8-K press release on November 14, 2026, announcing new clinical and real-world data presentations across its cardiometabolic health portfolio at ObesityWeek 2026, held November 14 to 17, 2026, in Washington, D.C.
The company said revenue in the period was affected by the federal export restriction on black mass, which limited its ability to sell certain materials. It said it received approval to export US$100 million of black mass product and expects revenue to begin recovering …
Interest income was US$4,629 thousand versus US$2,254 thousand. Net loss was US$(35,055) thousand, versus US$(25,175) thousand, or US$(0.42) per common share versus US$(0.48). Weighted average shares were 71,763,164 versus 39,584,489.
Mining margin was 50.7%, versus 29.0% in the second quarter of 2026 and 49.0% in the third quarter of 2025. Energy cost to mine one Bitcoin, net of curtailment and energy sales, was approximately US$35,000 versus approximately US$58,000, and blended net power cost was …
These increases were partly offset by a US$1.8 million decrease for its ENSUREClinical Trialsand a US$1.0 million decrease for its CALLIPER clinical trial.
Cost of revenues was US$16,402,500 versus US$12,741,748, equal to 28.00% ofRevenueversus 29.39%.Gross Profitwas US$42,179,020 versus US$30,611,487, or 72.00% of revenue versus 70.61%.
The company said it continued to prioritize PDS0301, its investigational tumor-targeted IL-12 immunocytokine, as its lead development program, with ongoingClinical Trialsat the National Cancer Institute.